Xianxin Hua's research lab at the University of Pennsylvania focuses on developing innovative immunotherapies for treating acute myeloid leukemia (AML). The lab is particularly interested in creating CAR T cells that target specific proteins on AML cells to improve treatment effectiveness while minimizing damage to healthy cells. Their work aims to translate new findings into clinical applications to offer better therapeutic options for patients with refractory AML.

Dr. Montserrat C Anguera's lab at the University of Pennsylvania focuses on understanding why females are more prone to developing systemic lupus erythematosus, an autoimmune disease. The lab studies how the X-chromosome, which carries many immunity-related genes, behaves differently in female B cells, particularly under chronic inflammation conditions. By examining gene regulation processes and epigenetic changes, they aim to reveal new insights into disease mechanisms and potential therapeutic targets for lupus.

Dr. Sydney Shaffer's lab at the University of Pennsylvania studies Barrett's esophagus, a condition that can lead to esophageal cancer. They focus on understanding how this condition progresses from non-dysplastic to dysplastic stages, which is crucial for developing better diagnostic tools and therapies. By using advanced techniques like single-cell analysis and 3D organoid models, their research aims to uncover the molecular changes that occur during this progression and identify potential targets for intervention.

Dr. William A. Beltran’s lab focuses on understanding and treating inherited retinal diseases, which can cause blindness. They work primarily with canine models that mimic these human diseases, helping to unravel the genetic and molecular basis of conditions like retinitis pigmentosa. By developing new therapies based on their findings, they aim to improve the quality of life for patients with these previously untreatable conditions.

Dr. Igor Brodsky's lab at the University of Pennsylvania focuses on how the immune system responds to infections by bacteria like Yersinia. His team studies the formation of granulomas, which are organized clusters of immune cells that help contain infections. By understanding the role of specific immune cells like inflammatory monocytes and signaling molecules such as IL-1, the lab aims to uncover mechanisms that control bacterial infections and influence public health.

Dr. Roger A Greenberg's lab at the University of Pennsylvania focuses on understanding how cancer cells with genomic instability can stimulate immune responses. They study the interactions between damaged DNA in cancer cells and the immune system, which can affect tumor growth and immune therapy effectiveness. The lab employs a multidisciplinary approach, integrating various techniques to explore these relationships and develop new therapies for cancer.

Dr. M. Celeste Simon's lab focuses on understanding clear cell renal cell carcinoma (ccRCC), a common type of kidney cancer characterized by significant metabolic changes. The lab studies how these metabolic alterations impact tumor behavior and explores new therapeutic strategies to improve treatment outcomes for patients with not only ccRCC but also other related cancers. By utilizing advanced models, they aim to uncover universal metabolic pathways that could be targeted for personalized cancer therapy.

Dr. Donita C. Brady's lab at the University of Pennsylvania focuses on understanding cancer biology through a novel approach that combines chemistry and biology. The lab is developing a platform called Probe Enabled Activity Reporting (PEAR) to analyze dynamic changes in the tumor proteome, with the aim of improving targeted therapies and precision oncology. By studying cancer at the proteome level, the lab aims to enhance our understanding of how tumors adapt to therapies and identify new treatment strategies.

Dr. Saba Ghassemi's research focuses on improving CAR T cell therapies for cancer treatment. The lab is investigating ways to enhance the effectiveness of non-activated CAR T cells by targeting signaling pathways that affect their durability and function. By modulating specific pathways, the lab aims to develop strategies that reduce cancer immune evasion and improve the overall clinical outcomes for patients receiving these therapies.

Dr. Carl H. June's lab at the University of Pennsylvania focuses on developing advanced immunotherapies for blood cancers, particularly through the use of chimeric antigen receptor (CAR) T cell therapies. Their innovative research aims to extend these therapies beyond current limits by combining CAR T cells with genetic editing techniques. The lab works on a range of hematologic malignancies, including multiple myeloma and acute myeloid leukemia, aiming to transform the treatment landscape for these challenging diseases.

Dr. Kenneth Zaret's lab focuses on the complex mechanisms that control how cells change their identity, particularly in liver development and regeneration. By studying proteins that regulate gene expression and the structures of chromosomes, the lab aims to uncover how cells can be reprogrammed for therapeutic purposes. Their research could lead to innovative strategies for treating diseases linked to cell fate, such as cancers and genetic disorders.

Dr. Yanxiang Deng's lab at the University of Pennsylvania focuses on studying the human hippocampus and its role in aging and Alzheimer's Disease. The lab is developing innovative technologies to analyze the complex cellular environments in brain tissue, aiming to uncover how different cell types contribute to memory impairment and disease progression. By combining multiple molecular profiling techniques, the lab hopes to identify potential new strategies for treatment and deepen our understanding of brain health.

Dr. Shelley L. Berger's lab at the University of Pennsylvania focuses on understanding the link between epigenetics and metabolism in cancer. The lab studies how changes in these pathways can affect gene expression and contribute to cancer development. They aim to develop new therapeutic strategies by investigating the role of specific enzymes and regulatory elements in these processes.

Dr. Jonathan A. Epstein's lab at the University of Pennsylvania focuses on designing advanced immune therapies to improve cardiac health. Specifically, the research targets the engineering of T regulatory cells to combat inflammation and fibrosis in the heart after events such as myocardial infarction, which can lead to heart failure. Through innovative techniques like lipid nanoparticle delivery, the lab aims to enhance the healing process and overall heart function.

Dr. Wei Guo's lab at the University of Pennsylvania focuses on understanding exosomes, which are tiny vesicles secreted by cells that play a crucial role in communication between cells. These exosomes carry molecules that can influence how other cells behave, impacting important processes such as cancer progression and immune responses. The lab investigates the mechanisms behind exosome secretion and how this process may be manipulated for therapeutic purposes, including potential cancer treatments.

Professor Serge Fuchs leads a lab focused on enhancing the effectiveness of CAR T cell therapy for solid tumors in cancer treatment. His research investigates how the tumor microenvironment suppresses CAR T cells and aims to develop strategies to improve their viability and anti-tumor efficacy. The lab employs various molecular techniques to understand these mechanisms and explore new interventions that could make CAR T therapy more successful against challenging cancer types.

Dr. Jorge Henao-Mejia's lab at the University of Pennsylvania focuses on understanding how early life exposures, particularly to glucocorticoids (stress hormones), influence the immune system and its response to diseases. They investigate how these exposures can reshape immune cells like monocytes and macrophages, linking them to conditions such as obesity, diabetes, allergies, and cancer. The lab employs advanced methods including genomics and single-cell analysis to uncover the mechanisms by which these changes happen and their implications for health.

Dr. Kathleen T. Montone's lab at the University of Pennsylvania focuses on collecting high-quality human tissue samples to support biomedical research in various diseases, particularly cancer and autoimmunity. The lab operates as part of the Cooperative Human Tissue Network, providing essential resources for researchers. By facilitating access to well-characterized biospecimens, the lab aims to foster innovation in diagnostics and therapeutics that can ultimately enhance public health.

Dr. Christopher Hunter's lab focuses on understanding immune responses to intestinal infections, particularly from the parasite Cryptosporidium, which poses serious health risks to children and individuals with immune deficiencies. The team explores the roles of immune molecules and pathways, such as CD40L and IL-22, in developing protective immunity, with the goal of guiding vaccine development and improving infection management. Through innovative techniques like parasite genetics and mouse models, they aim to harness the immune system to improve health against gastrointestinal diseases.

Dr. Chengcheng Jin's lab focuses on understanding how neutrophils, a type of immune cell, behave in the context of cancer. They investigate how these cells change their function in the tumor microenvironment and how to selectively target the cancer-promoting activities of neutrophils while preserving their protective roles. Through advanced techniques, the lab aims to uncover new targets for cancer therapies that can effectively modulate neutrophil function without compromising immune health.